{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:35:26Z","timestamp":1787510126307,"version":"build-2736575974"},"reference-count":151,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T00:00:00Z","timestamp":1675728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Intestinal bacteria coexist with humans and play a role in suppressing the invasion of pathogens, producing short-chain fatty acids, producing vitamins, and controlling the immune system. Studies have been carried out on culturable bacterial species using bacterial culture methods for many years. However, as metagenomic analysis of bacterial genes has been developed since the 1990s, it has recently revealed that many bacteria in the intestine cannot be cultured and that approximately 1,000 species and 40 trillion bacteria are present in the gut microbiota. Furthermore, the composition of the microbiota is different in each disease state compared with the healthy state, and dysbiosis has received much attention as a cause of various diseases. Regarding gastrointestinal diseases, dysbiosis has been reported to be involved in inflammatory bowel disease, irritable bowel syndrome, and non-alcoholic steatohepatitis. Recent findings have also suggested that dysbiosis is involved in colon cancer, liver cancer, pancreatic cancer, esophageal cancer, and so on. This review focuses on the relationship between the gut microbiota and gastrointestinal\/hepatobiliary diseases and also discusses new therapies targeting the gut microbiota.<\/jats:p>","DOI":"10.3389\/fmed.2022.935676","type":"journal-article","created":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T00:22:22Z","timestamp":1675729342000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Gastrointestinal disorders and intestinal bacteria: Advances in research and applications in therapy"],"prefix":"10.3389","volume":"9","author":[{"given":"Toshifumi","family":"Ohkusa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuriko","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1038\/ng.717","article-title":"Genome-wide meta-analysis increases to 71 the number of confirmed Crohn\u2019s disease susceptibility loci.","volume":"42","author":"Franke","year":"2010","journal-title":"Nat Genet."},{"key":"B2","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/ng.764","article-title":"Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47.","volume":"43","author":"Anderson","year":"2011","journal-title":"Nat Genet."},{"key":"B3","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/nature10209","article-title":"Genetics and pathogenesis of inflammatory bowel disease.","volume":"474","author":"Khor","year":"2011","journal-title":"Nature."},{"key":"B4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.it.2010.12.007","article-title":"The ever-expanding function of NOD2: autophagy, viral recognition, and T cell activation.","volume":"32","author":"Shaw","year":"2011","journal-title":"Trends Immunol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1002\/ibd.21537","article-title":"Antimicrobial peptide response to blood translocation of bacterial DNA in Crohn\u2019s disease is affected by NOD2\/CARD15 genotype.","volume":"17","author":"Guti\u00e9rrez","year":"2011","journal-title":"Inflamm Bowel Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/ni.1722","article-title":"Crohn\u2019s disease-associated NOD2 mutationsuppresses transcription of human IL10 by inhibiting activity of the nuclear ribonucleoproteinhnRNP-A1.","volume":"10","author":"Noguchi","year":"2009","journal-title":"Nat Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/nm.2069","article-title":"NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation.","volume":"16","author":"Cooney","year":"2010","journal-title":"Nat Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/ni.1823","article-title":"Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry.","volume":"11","author":"Travassos","year":"2010","journal-title":"Nat Immunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1136\/gutjnl-2012-303557","article-title":"Genetic susceptibility to increased bacterial translocation influences the response to biological therapy in patients with Crohn\u2019s disease.","volume":"63","author":"Guti\u00e9rrez","year":"2014","journal-title":"Gut."},{"key":"B10","doi-asserted-by":"publisher","first-page":"666e","DOI":"10.1016\/j.cell.2020.09.009","article-title":"Translocation of viable gut microbiota to mesenteric adipose drives formation of creeping fat in humans.","volume":"183","author":"Ha","year":"2020","journal-title":"Cell."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1949096","DOI":"10.1080\/19490976.2021.1949096.11","article-title":"Dysbiotic microbiota interactions in Crohn\u2019s disease.","volume":"13","author":"Caparr\u00f3s","year":"2021","journal-title":"Gut Microbes."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1136\/gutjnl-2018-317571","article-title":"Structural weakening of the colonic mucus barrier is an early event in ulcerative colitis pathogenesis.","volume":"68","author":"Van der Post","year":"2019","journal-title":"Gut."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1172e","DOI":"10.1016\/j.cell.2022.02.013","article-title":"Mucus sialylation determines intestinal host-commensal homeostasis.","volume":"185","author":"Yao","year":"2022","journal-title":"Cell."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.2337\/db07-1403","article-title":"Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice.","volume":"57","author":"Cani","year":"2008","journal-title":"Diabetes."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1038\/ng.221","article-title":"Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility.","volume":"40","author":"Franke","year":"2008","journal-title":"Nat Genet."},{"key":"B16","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/0092-8674(93)80068-p","article-title":"Interleukin-10-deficient mice develop chronic enterocolitis.","volume":"75","author":"K\u00fchn","year":"1993","journal-title":"Cell."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1056\/NEJMoa0907206","article-title":"Inflammatory bowel disease and mutations affecting the interleukin-10 receptor.","volume":"361","author":"Glocker","year":"2009","journal-title":"N Engl J Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1053\/gast.2002.34155","article-title":"Lack of common NOD2 variants in Japanese patients with Crohn\u2019s disease.","volume":"123","author":"Inoue","year":"2002","journal-title":"Gastroenterology."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1002\/ibd.21845","article-title":"Genetics of inflammatory bowel disease in Asia: systematic review and meta-analysis.","volume":"18","author":"Ng","year":"2012","journal-title":"Inflamm Bowel Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s00535-019-01618-1","article-title":"Manipulating resident microbiota to enhance regulatory immune function to treat inflammatory bowel diseases.","volume":"55","author":"Mishima","year":"2019","journal-title":"J Gastroenterol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.jiac.2015.07.010","article-title":"Intestinal microbiota and ulcerative colitis.","volume":"21","author":"Ohkusa","year":"2015","journal-title":"J Infect Chemother."},{"key":"B22","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/s41591-018-0308-z","article-title":"Microbial network disturbances in relapsing refractory Crohn\u2019s disease.","volume":"25","author":"Yilmaz","year":"2019","journal-title":"Nat Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/0016-5085(93)91016-b","article-title":"Reducing sulfur compounds of the colon impair colonocyte nutrition: implications for ulcerative colitis.","volume":"104","author":"Roediger","year":"1993","journal-title":"Gastroenterology."},{"key":"B24","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1136\/gut.36.6.897","article-title":"Significance of systemic endotoxaemia in inflammatory bowel disease.","volume":"36","author":"Gardiner","year":"1995","journal-title":"Gut."},{"key":"B25","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1136\/gut.34.4.437","article-title":"Sulphate reducing bacteria and hydrogen metabolism in the human large intestine.","volume":"34","author":"Gibson","year":"1993","journal-title":"Gut."},{"key":"B26","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/j.1574-6941.2002.tb00942.x","article-title":"Sulfate-reducing bacteria in human feces and their association with inflammatory bowel diseases.","volume":"40","author":"Loubinoux","year":"2002","journal-title":"FEMS Microbiol Ecol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1136\/gut.46.1.64","article-title":"The contribution of sulphate-reducing bacteria and 5-aminosalicylic acid to faecal sulphide in patients with ulcerative colitis.","volume":"46","author":"Pitcher","year":"2000","journal-title":"Gut."},{"key":"B28","doi-asserted-by":"publisher","first-page":"448","DOI":"10.3389\/fphys.2012.00448","article-title":"Microbial pathways in colonic sulfur metabolism and links with health and disease.","volume":"3","author":"Carbonero","year":"2012","journal-title":"Front Physiol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1136\/gutjnl-2015-310746","article-title":"Fungal microbiota dysbiosis in IBD.","volume":"66","author":"Sokol","year":"2017","journal-title":"Gut."},{"key":"B30","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.chom.2019.01.007","article-title":"Malassezia is associated with Crohn\u2019s disease and exacerbates colitis in mouse models.","volume":"25","author":"Limon","year":"2019","journal-title":"Cell Host Microbe."},{"key":"B31","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1046\/j.1440-1746.2000.02045.x","article-title":"Characterization of antibody responses against rectal mucosa-associated bacterial flora in patients with ulcerative colitis.","volume":"15","author":"Matsuda","year":"2000","journal-title":"J Gastroenterol Hepatol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1046\/j.1440-1746.2002.02834.x","article-title":"Fusobacterium varium localized in the colonic mucosa of patients with ulcerative colitis stimulates species-specific antibody.","volume":"17","author":"Ohkusa","year":"2002","journal-title":"J Gastroenterol Hepatol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1053\/gast.2002.30294","article-title":"Mucosal flora in inflammatory bowel disease.","volume":"122","author":"Swidsinski","year":"2002","journal-title":"Gastroenterology."},{"key":"B34","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/j.1440-1746.1993.tb01184.x","article-title":"Bacterial invasion into the colonic mucosa in ulcerative colitis.","volume":"8","author":"Ohkusa","year":"1993","journal-title":"J Gastroenterol Hepatol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1136\/gut.52.1.79","article-title":"Induction of experimental ulcerative colitis by Fusobacterium varium isolated from colonic mucosa of patients with ulcerative colitis.","volume":"52","author":"Ohkusa","year":"2003","journal-title":"Gut."},{"key":"B36","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1002\/ijc.2910600322","article-title":"Apoptosis in colorectal tumour cells: induction by the short chain fatty acids butyrate, propionate and acetate and by the bile salt deoxycholate.","volume":"60","author":"Hague","year":"1995","journal-title":"Int J Cancer."},{"key":"B37","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1128\/iai.32.2.458-463.1981","article-title":"Butyrate and propionate: important components of toxic dental plaque extracts.","volume":"32","author":"Singer","year":"1981","journal-title":"Infect Immun."},{"key":"B38","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1128\/iai.47.3.697-703.1985","article-title":"Experimental cecitis in gnotoxenic chickens monoassociated with Clostridium butyricum strains isolated from patients with neonatal necrotizing enterocolitis.","volume":"47","author":"Popoff","year":"1985","journal-title":"Infect Immun."},{"key":"B39","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1099\/jmm.0.005801-0","article-title":"Commensal bacteria can enter colonic epithelial cells and induce proinflammatory cytokine secretion: a possible pathogenic mechanism of ulcerative colitis.","volume":"58","author":"Ohkusa","year":"2009","journal-title":"J Med Microbiol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"e0189319","DOI":"10.1371\/journal.pone.0189319","article-title":"Characterization of Fusobacterium varium Fv113-g1 isolated from a patient with ulcerative colitis based on complete genome sequence and transcriptome analysis.","volume":"12","author":"Sekizuka","year":"2017","journal-title":"PLoS One."},{"key":"B41","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.cgh.2007.01.001","article-title":"Dysbiosis in pouchitis: evidence of unique microfloral patterns in pouch inflammation.","volume":"5","author":"Komanduri","year":"2007","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1053\/j.gastro.2015.05.041","article-title":"Pouch inflammation is associated with a decrease in specific bacterial taxa.","volume":"149","author":"Reshef","year":"2015","journal-title":"Gastroenterology."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1053\/j.gastro.2018.12.001","article-title":"Specific bacteria and metabolites associated with response to fecal microbiota transplantation in patients with ulcerative colitis.","volume":"156","author":"Paramsothy","year":"2019","journal-title":"Gastroenterology."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1080\/00365520510023648","article-title":"Effectiveness of antibiotic combination therapy in patients with active ulcerative colitis: a randomized, controlled pilot trial with long-term follow-up.","volume":"40","author":"Ohkusa","year":"2005","journal-title":"Scand J Gastroenterol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1038\/ajg.2010.84","article-title":"Newly developed antibiotic combination therapy for ulcerative colitis: a double-blind placebo-controlled multicenter trial.","volume":"105","author":"Ohkusa","year":"2010","journal-title":"Am J Gastroenterol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1007\/bf01317078","article-title":"Possible role of mycobacteria in inflammatory bowel disease. I. An unclassified Mycobacterium species isolated from patients with Crohn\u2019s disease.","volume":"29","author":"Chiodini","year":"1984","journal-title":"Dig Dis Sci."},{"key":"B47","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1136\/gut.33.7.890","article-title":"Mycobacterium paratuberculosis DNA in Crohn\u2019s disease tissue.","volume":"33","author":"Sanderson","year":"1992","journal-title":"Gut."},{"key":"B48","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1136\/gut.51.5.665","article-title":"PCR detection of Mycobacterium paratuberculosis in Crohn\u2019s disease granulomas isolated by laser capture microdissection.","volume":"51","author":"Ryan","year":"2002","journal-title":"Gut."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/s0140-6736(04)17058-x","article-title":"Culture of Mycobacterium avium subspecies paratuberculosis from the blood of patients with Crohn\u2019s disease.","volume":"364","author":"Naser","year":"2004","journal-title":"Lancet."},{"key":"B50","doi-asserted-by":"publisher","first-page":"473e","DOI":"10.1053\/j.gastro.2011.11.032","article-title":"Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn\u2019s disease.","volume":"142","author":"Prantera","year":"2012","journal-title":"Gastroenterology."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/s0016-5085(98)70019-8","article-title":"Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn\u2019s disease.","volume":"115","author":"Darfeuille-Michaud","year":"1998","journal-title":"Gastroenterology."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1002\/ibd.21606","article-title":"Invasive potential of gut mucosa-derived Fusobacterium nucleatum positively correlates with IBD status of the host.","volume":"17","author":"Strauss","year":"2011","journal-title":"Inflamm Bowel Dis."},{"key":"B53","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1126\/science.aan4526","article-title":"Ectopic colonization of oral bacteria in the intestine drives T(H)1 cell induction and inflammation.","volume":"358","author":"Atarashi","year":"2017","journal-title":"Science."},{"key":"B54","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1016\/j.cell.2022.07.003","article-title":"Targeted suppression of human IBD-associated gut microbiota commensals by phage consortia for treatment of intestinal inflammation.","volume":"185","author":"Federici","year":"2022","journal-title":"Cell."},{"key":"B55","first-page":"307","article-title":"The irritable colon syndrome. A study of the clinical features, predisposing causes, and prognosis in 130 cases.","volume":"31","author":"Chaudhary","year":"1962","journal-title":"Q J Med."},{"key":"B56","first-page":"185","article-title":"The fecal microbial population in the irritable bowel syndrome.","volume":"5","author":"Balsari","year":"1982","journal-title":"Microbiologica."},{"key":"B57","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/j.1572-0241.2003.07234.x","article-title":"Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. A double-blind, randomized, placebo-controlled study.","volume":"98","author":"Pimentel","year":"2003","journal-title":"Am J Gastroenterol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1053\/j.gastro.2016.08.003","article-title":"Repeat treatment with rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome.","volume":"151","author":"Lembo","year":"2016","journal-title":"Gastroenterology."},{"key":"B59","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1053\/j.gastro.2019.03.049","article-title":"Gut microbiota in patients with irritable bowel syndrome-a systematic review.","volume":"157","author":"Pittayanon","year":"2019","journal-title":"Gastroenterology."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1007\/s10620-011-1590-5","article-title":"Methane on breath testing is associated with constipation: a systematic review and meta-analysis.","volume":"56","author":"Kunkel","year":"2011","journal-title":"Dig Dis Sci."},{"key":"B61","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1097\/MCG.0b013e3181c64c90","article-title":"A combination of rifaximin and neomycin is most effective in treating irritable bowel syndrome patients with methane on lactulose breath test.","volume":"44","author":"Low","year":"2010","journal-title":"J Clin Gastroenterol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1136\/gutjnl-2018-317416","article-title":"Serine proteases as luminal mediators of intestinal barrier dysfunction and symptom severity in IBS.","volume":"69","author":"Edogawa","year":"2020","journal-title":"Gut."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1016e","DOI":"10.1053\/j.gastro.2019.11.301","article-title":"Differences in fecal microbiomes and metabolomes of people with vs without irritable bowel syndrome and bile acid malabsorption.","volume":"158","author":"Jeffery","year":"2020","journal-title":"Gastroenterology."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1093\/jnci\/djt349","article-title":"Need for prospective cohort studies to establish human gut microbiome contributions to disease risk.","volume":"105","author":"Mai","year":"2013","journal-title":"J Natl Cancer Inst."},{"key":"B65","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1111\/codi.12662","article-title":"Streptococcus bovis infection and colorectal neoplasia: a meta-analysis.","volume":"16","author":"Krishnan","year":"2014","journal-title":"Colorectal Dis."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1093\/jnci\/djt300","article-title":"Human gut microbiome and risk for colorectal cancer.","volume":"105","author":"Ahn","year":"2013","journal-title":"J Natl Cancer Inst."},{"key":"B67","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1101\/gr.126573.111","article-title":"Genomic analysis identifies association of Fusobacterium with colorectal carcinoma.","volume":"22","author":"Kostic","year":"2012","journal-title":"Genome Res."},{"key":"B68","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1101\/gr.126516.111","article-title":"Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma.","volume":"22","author":"Castellarin","year":"2012","journal-title":"Genome Res."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1126\/science.aal5240","article-title":"Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer.","volume":"358","author":"Bullman","year":"2017","journal-title":"Science."},{"key":"B70","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1038\/s41591-019-0458-7","article-title":"Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer.","volume":"25","author":"Yachida","year":"2019","journal-title":"Nat Med."},{"key":"B71","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/s41591-019-0405-7","article-title":"Metagenomic analysis of colorectal cancer datasets identifies cross-cohort microbial diagnostic signatures and a link with choline degradation.","volume":"25","author":"Thomas","year":"2019","journal-title":"Nat Med."},{"key":"B72","doi-asserted-by":"publisher","first-page":"e0212406","DOI":"10.1371\/journal.pone.0212406","article-title":"Metagenomic analyses of the gut microbiota associated with colorectal adenoma.","volume":"14","author":"Saito","year":"2019","journal-title":"PLoS One."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1136\/gutjnl-2019-319635","article-title":"Southern Chinese populations harbour non-nucleatum Fusobacteria possessing homologues of the colorectal cancer-associated FadA virulence factor.","volume":"69","author":"Yeoh","year":"2020","journal-title":"Gut."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1053\/j.gastro.2019.12.029","article-title":"Association between sulfur-metabolizing bacterial communities in stool and risk of distal colorectal cancer in men.","volume":"158","author":"Nguyen","year":"2020","journal-title":"Gastroenterology."},{"key":"B75","doi-asserted-by":"publisher","first-page":"708e","DOI":"10.1016\/j.ccell.2021.03.004","article-title":"Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver.","volume":"39","author":"Bertocchi","year":"2021","journal-title":"Cancer Cell."},{"key":"B76","doi-asserted-by":"publisher","first-page":"5574","DOI":"10.1158\/1078-0432.ccr-16-1786","article-title":"Human microbiome Fusobacterium nucleatum in esophageal cancer tissue is associated with prognosis.","volume":"22","author":"Yamamura","year":"2016","journal-title":"Clin Cancer Res."},{"key":"B77","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13027-016-0049-x","article-title":"Presence of Porphyromonas gingivalis in esophagus and its association with the clinicopathological characteristics and survival in patients with esophageal cancer.","volume":"11","author":"Gao","year":"2016","journal-title":"Infect Agent Cancer."},{"key":"B78","doi-asserted-by":"publisher","first-page":"6777","DOI":"10.1158\/0008-5472.can-17-1296","article-title":"Oral microbiome composition reflects prospective risk for esophageal cancers.","volume":"77","author":"Peters","year":"2017","journal-title":"Cancer Res."},{"key":"B79","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/cncr.33316","article-title":"Oral infectious bacteria in dental plaque and saliva as risk factors in patients with esophageal cancer.","volume":"127","author":"Kawasaki","year":"2020","journal-title":"Cancer."},{"key":"B80","first-page":"237","article-title":"Small intestinal ulcers and intestinal flora in rats given indomethacin.","volume":"54","author":"Kent","year":"1969","journal-title":"Am J Pathol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s00204-006-0149-2","article-title":"Role of bile in pathogenesis of indomethacin-induced enteropathy.","volume":"81","author":"Jacob","year":"2007","journal-title":"Arch Toxicol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/0090-6980(77)90178-2","article-title":"Resistance of germfree rats to indomethacin-induced intestinal lesions.","volume":"14","author":"Robert","year":"1977","journal-title":"Prostaglandins."},{"key":"B83","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1111\/j.1348-0421.1996.tb01108.x","article-title":"Role of intestinal bacteria in ileal ulcer formation in rats treated with a nonsteroidal antiinflammatory drug.","volume":"40","author":"Uejima","year":"1996","journal-title":"Microbiol Immunol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"637.e","DOI":"10.1053\/j.gastro.2019.05.008","article-title":"Bifidobacterium breve Bif195 protects against small-intestinal damage caused by acetylsalicylic acid in healthy volunteers.","volume":"157","author":"Mortensen","year":"2019","journal-title":"Gastroenterology."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1111\/j.1572-0241.2001.03702.x","article-title":"Obesity and female gender increase breath ethanol concentration: potential implications for the pathogenesis of nonalcoholic steatohepatitis.","volume":"96","author":"Nair","year":"2001","journal-title":"Am J Gastroenterol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1053\/j.gastro.2020.10.056","article-title":"Chronic liver diseases and the microbiome-translating our knowledge of gut microbiota to management of chronic liver disease.","volume":"160","author":"Acharya","year":"2021","journal-title":"Gastroenterology."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1053\/jhep.2001.24236","article-title":"Promoter polymorphism of the CD14 endotoxin receptor gene as a risk factor for alcoholic liver disease.","volume":"33","author":"J\u00e4rvel\u00e4inen","year":"2001","journal-title":"Hepatology."},{"key":"B88","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1136\/gutjnl-2019-318811","article-title":"Intrahepatic bacterial metataxonomic signature in non-alcoholic fatty liver disease.","volume":"69","author":"Sookoian","year":"2020","journal-title":"Gut."},{"key":"B89","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nature10809","article-title":"Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity.","volume":"482","author":"Henao-Mejia","year":"2012","journal-title":"Nature."},{"key":"B90","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1002\/hep.26093","article-title":"Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH.","volume":"57","author":"Zhu","year":"2013","journal-title":"Hepatology."},{"key":"B91","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1111\/j.1572-0241.2002.05791.x","article-title":"Small intestinal bacterial overgrowth in human cirrhosis is associated with systemic endotoxemia.","volume":"97","author":"Bauer","year":"2002","journal-title":"Am J Gastroenterol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1002\/hep.26319","article-title":"Intestinal microbiota in patients with nonalcoholic fatty liver disease.","volume":"58","author":"Mouzaki","year":"2013","journal-title":"Hepatology."},{"key":"B93","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1053\/j.gastro.2014.01.020","article-title":"Interactions between the intestinal microbiome and liver diseases.","volume":"146","author":"Schnabl","year":"2014","journal-title":"Gastroenterology."},{"key":"B94","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1111\/apt.13164","article-title":"Review article: alcohol and gut microbiota - the possible role of gut microbiota modulation in the treatment of alcoholic liver disease.","volume":"41","author":"Vassallo","year":"2015","journal-title":"Aliment Pharmacol Ther."},{"key":"B95","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/apt.15416","article-title":"Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease.","volume":"50","author":"Koopman","year":"2019","journal-title":"Aliment Pharmacol Ther."},{"key":"B96","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S1665-2681(19)31364-X","article-title":"Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study.","volume":"12","author":"Wong","year":"2013","journal-title":"Ann Hepatol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"e000315","DOI":"10.1136\/bmjgast-2019-000315","article-title":"High potency multistrain probiotic improves liver histology in non-alcoholic fatty liver disease (NAFLD): a randomised, double-blind, proof of concept study.","volume":"6","author":"Duseja","year":"2019","journal-title":"BMJ Open Gastroenterol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1007\/s00394-018-1721-2","article-title":"Histological improvement of non-alcoholic steatohepatitis with a prebiotic: a pilot clinical trial.","volume":"58","author":"Bomhof","year":"2019","journal-title":"Eur J Nutr."},{"key":"B99","doi-asserted-by":"publisher","first-page":"5688","DOI":"10.1038\/s41598-019-42059-3","article-title":"Randomized, double-blind, placebo-controlled study of a multispecies probiotic mixture in nonalcoholic fatty liver disease.","volume":"9","author":"Ahn","year":"2019","journal-title":"Sci Rep."},{"key":"B100","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1002\/hep.24423","article-title":"Characterization of fecal microbial communities in patients with liver cirrhosis.","volume":"54","author":"Chen","year":"2011","journal-title":"Hepatology."},{"key":"B101","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jhep.2013.12.019","article-title":"Altered profile of human gut microbiome is associated with cirrhosis and its complications.","volume":"60","author":"Bajaj","year":"2014","journal-title":"J Hepatol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"301.e","DOI":"10.1016\/j.jcmgh.2019.04.008","article-title":"Predicting clinical outcomes of cirrhosis patients with hepatic encephalopathy from the fecal microbiome.","volume":"8","author":"Sung","year":"2019","journal-title":"Cell Mol Gastroenterol Hepatol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1097\/meg.0000000000001494","article-title":"Characterisation of blood microbiota in patients with liver cirrhosis.","volume":"31","author":"Kajihara","year":"2019","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"841281","DOI":"10.3389\/fmed.2022.841281","article-title":"Recent trends of microbiota-based microbial metabolites metabolism in liver disease.","volume":"9","author":"Ganesan","year":"2022","journal-title":"Front Med (Lausanne)."},{"key":"B105","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1056\/NEJMoa0907893","article-title":"Rifaximin treatment in hepatic encephalopathy.","volume":"362","author":"Bass","year":"2010","journal-title":"N Engl J Med."},{"key":"B106","doi-asserted-by":"publisher","first-page":"e94416","DOI":"10.1172\/jci.insight.94416","article-title":"Microbiota, cirrhosis, and the emerging oral-gut-liver axis.","volume":"2","author":"Acharya","year":"2017","journal-title":"JCI Insight."},{"key":"B107","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1136\/gutjnl-2016-312533","article-title":"Characterisation of the faecal microbiota in Japanese patients with paediatric-onset primary sclerosing cholangitis.","volume":"66","author":"Iwasawa","year":"2017","journal-title":"Gut."},{"key":"B108","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1136\/gutjnl-2015-311004","article-title":"Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD.","volume":"65","author":"Sabino","year":"2016","journal-title":"Gut."},{"key":"B109","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/apt.15375","article-title":"Consistent alterations in faecal microbiomes of patients with primary sclerosing cholangitis independent of associated colitis.","volume":"50","author":"R\u00fchlemann","year":"2019","journal-title":"Aliment Pharmacol Ther."},{"key":"B110","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1136\/gutjnl-2019-318416","article-title":"Alterations of the bile microbiome in primary sclerosing cholangitis.","volume":"69","author":"Liwinski","year":"2020","journal-title":"Gut."},{"key":"B111","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/s41564-018-0333-1","article-title":"Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis.","volume":"4","author":"Nakamoto","year":"2019","journal-title":"Nat Microbiol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.14309\/ajg.0000000000000115","article-title":"Fecal microbiota transplantation in patients with primary sclerosing cholangitis: a pilot clinical trial.","volume":"114","author":"Allegretti","year":"2019","journal-title":"Am J Gastroenterol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1093\/jnci\/djk021","article-title":"A prospective study of periodontal disease and pancreatic cancer in US male health professionals.","volume":"99","author":"Michaud","year":"2007","journal-title":"J Natl Cancer Inst."},{"key":"B114","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1136\/gutjnl-2012-303006","article-title":"Plasma antibodies to oral bacteria and risk of pancreatic cancer in a large European prospective cohort study.","volume":"62","author":"Michaud","year":"2013","journal-title":"Gut."},{"key":"B115","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1136\/gutjnl-2016-312580","article-title":"Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case-control study.","volume":"67","author":"Fan","year":"2018","journal-title":"Gut."},{"key":"B116","doi-asserted-by":"publisher","first-page":"7209","DOI":"10.18632\/oncotarget.3109","article-title":"Association of Fusobacterium species in pancreatic cancer tissues with molecular features and prognosis.","volume":"6","author":"Mitsuhashi","year":"2015","journal-title":"Oncotarget."},{"key":"B117","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1126\/science.aah5043","article-title":"Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine.","volume":"357","author":"Geller","year":"2017","journal-title":"Science."},{"key":"B118","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1158\/2159-8290.cd-17-1134","article-title":"The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression.","volume":"8","author":"Pushalkar","year":"2018","journal-title":"Cancer Discov."},{"key":"B119","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1136\/gutjnl-2021-324755","article-title":"A faecal microbiota signature with high specificity for pancreatic cancer.","volume":"71","author":"Kartal","year":"2022","journal-title":"Gut."},{"key":"B120","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.cell.2019.07.008","article-title":"Tumor microbiome diversity and composition influence pancreatic cancer outcomes.","volume":"178","author":"Riquelme","year":"2019","journal-title":"Cell."},{"key":"B121","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1136\/gutjnl-2018-317458","article-title":"Enrichment of oral microbiota in early cystic precursors to invasive pancreatic cancer.","volume":"68","author":"Gaiser","year":"2019","journal-title":"Gut."},{"key":"B122","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1016\/s0140-6736(08)60635-2","article-title":"Clostridium difficile infection.","volume":"371","author":"Kuipers","year":"2008","journal-title":"Lancet."},{"key":"B123","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1111\/apt.12699","article-title":"Systematic review: faecal microbiota transplantation therapy for digestive and nondigestive disorders in adults and children.","volume":"39","author":"Sha","year":"2014","journal-title":"Aliment Pharmacol Ther."},{"key":"B124","first-page":"854","article-title":"Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis.","volume":"44","author":"Eiseman","year":"1958","journal-title":"Surgery."},{"key":"B125","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1056\/NEJMoa1205037","article-title":"Duodenal infusion of donor feces for recurrent Clostridium difficile.","volume":"368","author":"Van Nood","year":"2013","journal-title":"N Engl J Med."},{"key":"B126","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S2468-1253(22)00276-X","article-title":"Faecal microbiota transplantation for first or second Clostridioides difficile infection (EarlyFMT): a randomised, double-blind, placebo-controlled trial.","volume":"7","author":"Baunwall","year":"2022","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"B127","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1038\/ajg.2014.133","article-title":"Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients.","volume":"109","author":"Kelly","year":"2014","journal-title":"Am J Gastroenterol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1016\/j.cgh.2013.12.032","article-title":"Efficacy of combined jejunal and colonic fecal microbiota transplantation for recurrent Clostridium difficile infection.","volume":"12","author":"Dutta","year":"2014","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B129","doi-asserted-by":"publisher","first-page":"e893","DOI":"10.1128\/mBio.00893-14","article-title":"Recovery of the gut microbiome following fecal microbiota transplantation.","volume":"5","author":"Seekatz","year":"2014","journal-title":"mBio."},{"key":"B130","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/s0140-6736(89)91183-5","article-title":"Treatment of ulcerative colitis by implantation of normal colonic flora.","volume":"1","author":"Bennet","year":"1989","journal-title":"Lancet."},{"key":"B131","doi-asserted-by":"publisher","first-page":"102.e","DOI":"10.1053\/j.gastro.2015.04.001","article-title":"Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial.","volume":"149","author":"Moayyedi","year":"2015","journal-title":"Gastroenterology."},{"key":"B132","doi-asserted-by":"publisher","first-page":"110.e","DOI":"10.1053\/j.gastro.2015.03.045","article-title":"Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis.","volume":"149","author":"Rossen","year":"2015","journal-title":"Gastroenterology."},{"key":"B133","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/s0140-6736(17)30182-4","article-title":"Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomized placebo-controlled trial.","volume":"389","author":"Paramsothy","year":"2017","journal-title":"Lancet."},{"key":"B134","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1001\/jama.2018.20046","article-title":"Effect of fecal microbiota transplantation on 8-week remission in patients with ulcerative colitis: a randomized clinical trial.","volume":"321","author":"Costello","year":"2019","journal-title":"JAMA."},{"key":"B135","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1097\/mib.0000000000000975","article-title":"Changes in intestinal microbiota following combination therapy with fecal microbial transplantation and antibiotics for ulcerative colitis.","volume":"23","author":"Ishikawa","year":"2017","journal-title":"Inflamm Bowel Dis."},{"key":"B136","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1093\/ibd\/izy266","article-title":"The microbial composition of Bacteroidetes species in ulcerative colitis is effectively improved by combination therapy with fecal microbiota transplantation and antibiotics.","volume":"24","author":"Ishikawa","year":"2018","journal-title":"Inflamm Bowel Dis."},{"key":"B137","doi-asserted-by":"publisher","first-page":"5517","DOI":"10.1038\/s41598-022-09307-5","article-title":"Strain-resolved analysis in a randomized trial of antibiotic pretreatment and maintenance dose delivery mode with fecal microbiota transplant for ulcerative colitis.","volume":"12","author":"Smith","year":"2022","journal-title":"Sci Rep."},{"key":"B138","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S2468-1253(21)00400-3","article-title":"Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial.","volume":"7","author":"Haifer","year":"2022","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"B139","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1093\/ecco-jcc\/jjab165","article-title":"Use of faecal transplantation with a novel diet for mild to moderate active ulcerative colitis: the CRAFT UC randomised controlled trial.","volume":"16","author":"Sarbagili Shabat","year":"2022","journal-title":"J Crohns Colitis."},{"key":"B140","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1093\/ibd\/izab001","article-title":"Fecal microbiota transplantation in chronic pouchitis: a randomized, parallel, double-blinded clinical trial.","volume":"27","author":"Karjalainen","year":"2021","journal-title":"Inflamm Bowel Dis."},{"key":"B141","doi-asserted-by":"publisher","first-page":"604","DOI":"10.5694\/j.1326-5377.1989.tb136704.x","article-title":"Bowel-flora alteration: a potential cure for inflammatory bowel disease and irritable bowel syndrome?","volume":"150","author":"Borody","year":"1989","journal-title":"Med J Aust."},{"key":"B142","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1093\/ecco-jcc\/jjx063","article-title":"Faecal microbiota transplantation for inflammatory bowel disease: a systematic review and meta-analysis.","volume":"11","author":"Paramsothy","year":"2017","journal-title":"J Crohns Colitis."},{"key":"B143","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s00253-018-9447-x","article-title":"Timing for the second fecal microbiota transplantation to maintain the long-term benefit from the first treatment for Crohn\u2019s disease.","volume":"103","author":"Li","year":"2019","journal-title":"Appl Microbiol Biotechnol."},{"key":"B144","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1136\/gutjnl-2018-316434","article-title":"Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study.","volume":"67","author":"Halkj\u00e6r","year":"2018","journal-title":"Gut."},{"key":"B145","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/s2468-1253(17)30338-2","article-title":"Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial.","volume":"3","author":"Johnsen","year":"2018","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"B146","doi-asserted-by":"publisher","first-page":"S130","DOI":"10.1016\/S0016-5085(18)30860-6","article-title":"Fecal microbiota transplantation in irritable bowel syndrome with predominant abdominal bloating: results from a double blind, placebo-controlled clinical trial.","volume":"154","author":"Holvoet","year":"2018","journal-title":"Gastroenterology."},{"key":"B147","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/s2468-1253(19)30198-0","article-title":"Faecal microbiota transplantation for diarrhoea-predominant irritable bowel syndrome: a double-blind, randomised, placebo-controlled trial.","volume":"4","author":"Aroniadis","year":"2019","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"B148","doi-asserted-by":"publisher","first-page":"e00034","DOI":"10.14309\/ctg.0000000000000034","article-title":"The effect of allogenic versus autologous fecal microbiota transfer on symptoms, visceral perception and fecal and mucosal microbiota in irritable bowel syndrome: a randomized controlled study.","volume":"10","author":"Holster","year":"2019","journal-title":"Clin Transl Gastroenterol."},{"key":"B149","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1136\/gutjnl-2019-319630","article-title":"Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study.","volume":"69","author":"El-Salhy","year":"2020","journal-title":"Gut."},{"key":"B150","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/apt.15116","article-title":"Systematic review with meta-analysis: review of donor features, procedures and outcomes in 168 clinical studies of faecal microbiota transplantation.","volume":"49","author":"Lai","year":"2019","journal-title":"Aliment Pharmacol Ther."},{"key":"B151","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1056\/NEJMoa1910437","article-title":"Drug-resistant E.coli bacteremia transmitted by fecal microbiota transplant.","volume":"381","author":"DeFilipp","year":"2019","journal-title":"N Engl J Med."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.935676\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T00:22:29Z","timestamp":1675729349000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.935676\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,7]]},"references-count":151,"alternative-id":["10.3389\/fmed.2022.935676"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.935676","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,7]]},"article-number":"935676"}}